ASGCT 2025: The Co-Founder of ProQR discusses the company's Axiomer RNA base editing technology - which will see a CTA filed this quarter and data by the end of the year

May 15, 2025
1 min read

ProQR Co-Founder & CSO Gerard Platenburg describes the company's RNA editing platform and the journey he has seen this field go through over time. Plus, updates on programs for cholestatic diseases, Rhett Syndrome, and MASH.

https://vimeo.com/1084665135

Recent Posts

See All

Quell Tx believes that restoring immune balance rather than entirely depleting cells is key for many autoimmune conditions - a phase 1/2 for its CAR-Treg initiated today in RA & Systemic Sclerosis

Protagonist Therapeutics has two medicines in front of FDA right now - we discuss the expertise in peptide based drug development that has enabled them to get to this point

Cambridge, UK based Arecor uses formulation and development expertise to improve the profile of medicines - the company believes it has its own best in class insulin leveraging this

ASGCT 2025: The Co-Founder of ProQR discusses the company's Axiomer RNA base editing technology - which will see a CTA filed this quarter and data by the end of the year

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight